The introduction of more effective anti-myeloma therapies has made it more important to think of a longer-term approach to treatment for a lot of patients. In this podcast, we speak to Associate Professor Sarah Holstein from University of Nebraska Medical Center, United States, and Dr Simon Gibbs from Australia about their overall treatment aims for patients with newly diagnosed multiple myeloma, and the need to think about the first-line treatment approach and how that can affect subsequent lines of therapy.

This podcast was sponsored by Celgene Pty Ltd. Views and opinions expressed in this presentation are those of the presenter alone, and do not necessarily reflect the views and opinions of Celgene or any employee thereof. This information is not medical advice and no decision relating to the management of any patient should be made with reliance on the information contained in this presentation. It is your responsibility to prescribe appropriate treatments in accordance with your clinical judgment and by reference to the appropriate Australian Product Information or other information supplied with the relevant product, including in relation to any indication, dosage, and route of administration.
The following developmental compounds mentioned within this podcast are not currently approved by the Therapeutic Goods Administration (Nov 2019) for Multiple Myeloma:
Bispecific T-Cell Engagers (BiTEs)
Chimeric Antigen Receptor T Cell (CAR-T)
Selinexor
Carfilzomib (newly diagnosed Multiple Myeloma)
Please review approved Revlimid product information.before prescribing.